These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24030791)

  • 1. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain.
    Kuehn BM
    JAMA; 2013 Oct; 310(15):1547-8. PubMed ID: 24129447
    [No Abstract]   [Full Text] [Related]  

  • 6. Pain treatment, drug diversion, and the casualties of war.
    Burgess F
    Pain Med; 2006; 7(6):474-5. PubMed ID: 17112360
    [No Abstract]   [Full Text] [Related]  

  • 7. Pain treatment agreements.
    Rowe W
    Am J Bioeth; 2010 Nov; 10(11):3-4. PubMed ID: 21104544
    [No Abstract]   [Full Text] [Related]  

  • 8. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic pain, addiction, and Zohydro.
    Olsen Y; Sharfstein JM
    N Engl J Med; 2014 May; 370(22):2061-3. PubMed ID: 24758596
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community.
    By K; McAninch JK; Keeton SL; Secora A; Kornegay CJ; Hwang CS; Ly T; Levenson MS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):473-478. PubMed ID: 28833803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Don't overlook directions.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Dec; 96(12):14-5. PubMed ID: 8961854
    [No Abstract]   [Full Text] [Related]  

  • 15. We can make opioids safer.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):112-3. PubMed ID: 23688516
    [No Abstract]   [Full Text] [Related]  

  • 16. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 17. US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.
    Mercadante S; Craig D; Giarratano A
    Drugs; 2012 Dec; 72(18):2327-32. PubMed ID: 23116252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and Limits of Abuse-Deterrent Painkillers.
    Hendrikson H; Hanson K
    NCSL Legisbrief; 2016 Feb; 24(6):1-2. PubMed ID: 27032127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Education becomes focus of classwide opioid REMS.
    Thompson CA
    Am J Health Syst Pharm; 2012 Aug; 69(16):1352. PubMed ID: 22855094
    [No Abstract]   [Full Text] [Related]  

  • 20. The Joint Commission and the FDA take steps to curb adverse events related to the use and misuse of opioid drugs.
    ED Manag; 2012 Oct; 24(10):112-6. PubMed ID: 23045763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.